Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Inger Boström"'
Autor:
Anne-Marie Landtblom, Thomas Fast, Inger Boström, Shala Ghaderi Berntsson, Anastasija Komkova, Helena Gauffin
Publikováno v:
Acta Neurologica Scandinavica. 145:185-192
Objectives To describe the pharmacological treatments (2005-2017) and the healthcare utilization (1997-2016) for patients with narcolepsy in Sweden in order to create a framework for future organizational and economic analyses. Material & Methods Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6070cd1265aaa403a76ef933b623cb
https://doi.org/10.1111/ane.13532
https://doi.org/10.1111/ane.13532
Publikováno v:
Analiz Riska Zdorovʹû, Iss 3, Pp 141-145 (2021)
Immunomodulatory drugs are important to control disease activity in relapsing-remitting multiple sclerosis (MS). Anti-CD 20-therapy is one of such medications. In Sweden, extensive off label prescription of rituximab (RTX) in MS has been documented;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102575b223cf6e3c1b9523ca15ae818c
https://doi.org/10.21668/health.risk/2021.3.14.eng
https://doi.org/10.21668/health.risk/2021.3.14.eng
Autor:
Kyla A. McKay, Inger Boström, Anne-Marie Landtblom, Cecilia Teljas, Ruth Ann Marrie, Ali Manouchehrinia, Jan Hillert
Publikováno v:
Acta neurologica ScandinavicaREFERENCES. 144(6)
Objectives Multiple sclerosis (MS) is a chronic neurodegenerative disease of the central nervous system. Identifying MS at the population level is important for disease surveillance and allocation of resources. The Swedish National Patient Registry (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce471a583b8fab5bf88a6acf6d81815
https://pubmed.ncbi.nlm.nih.gov/34357597
https://pubmed.ncbi.nlm.nih.gov/34357597
Autor:
K. M. Myhr, Maura Pugliatti, Kjetil Bjornevik, Inger Boström, Christina Wolfson, Trond Riise, A. M. Landtblom
Publikováno v:
Analiz Riska Zdorovʹû, Iss 3, Pp 60-66 (2019)
Results obtained in previous studies on the relationship between exposure to organic solvents and risk of multiple sclerosis are not entirely consistent. The aim of this study was to investigate the relationship between exposure to organic solvents a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2fa55b2e09d75ac5c308d1a4b2380ea
http://journal.fcrisk.ru/eng/2019/3/7
http://journal.fcrisk.ru/eng/2019/3/7
Publikováno v:
Acta Neurologica Scandinavica
The COVID‐19 pandemic has brought challenges for healthcare management of patients with multiple sclerosis (MS). Concerns regarding vulnerability to infections and disease‐modifying therapies (DMTs) and their complications have been raised. Recen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbfb1c4a10ca78c2cdf0c8c6678232d4
http://europepmc.org/articles/PMC8222873
http://europepmc.org/articles/PMC8222873
Autor:
Anne-Marie Landtblom, Trond Riise, Kristin Wesnes, Kjetil Bjornevik, Maura Pugliatti, Marianna Cortese, Inger Boström, Christina Wolfson, Kjell-Morten Myhr
Publikováno v:
Multiple Sclerosis Journal. 24:150-157
Background: The lifestyle factors smoking and obesity have been associated with the risk of multiple sclerosis (MS). Physical activity (PA) may also be of importance. Objective: To examine the association between PA and MS risk in Italy, Norway, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b233edeb412f96579a8b970d9f60fdd
https://doi.org/10.1177/1352458517694088
https://doi.org/10.1177/1352458517694088
Publikováno v:
Revue neurologique. 175(10)
Organic solvents exposure has for a long time been suspected as a risk factor for developing multiple sclerosis. The evidence, containing case reports, case-control studies and cohort studies has been contradictory. An early meta-analysis, however, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64dd5da997c3335931821589dbcf746a
https://pubmed.ncbi.nlm.nih.gov/31676154
https://pubmed.ncbi.nlm.nih.gov/31676154
Autor:
Anne-Marie Landtblom, Inger Boström, Shala Ghaderi Berntsson, Joachim Burman, A. Kristoffersson, Amalia Feresiadou
Publikováno v:
Acta neurologica Scandinavica. 138(4)
OBJECTIVES Off-label use of rituximab to treat MS patients in Sweden is high, and the need for long-term safety data may not be met. Our objectives were to assess the rate of rituximab prescription in patients with multiple sclerosis in Sweden and, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d346312c7040d8a41f07b45064a4f278
https://pubmed.ncbi.nlm.nih.gov/29797711
https://pubmed.ncbi.nlm.nih.gov/29797711